Palomino Labs (PALX) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PALX SEC filings page.
This page shows Palomino Labs Inc (PALX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Palomino’s 2025 balance-sheet expansion was financed externally, while operations still produced losses and consumed cash.
Financing dependence is the central pattern: FY2025 financing cash flow reached$9.3M while operating cash flow was negative$1.3M , so the enlarged balance sheet was not funded by internal operations. At the same time, the net loss of$3.2M exceeded operating cash outflow, indicating that accounting expenses included costs not fully reflected in that year’s operating cash movement.
The capital structure changed sharply by FY2025:
Operating scale remains unestablished in the reported data because revenue is not provided, while selling, general and administrative expense reached
Financial Health Signals
We do not publish a peer-relative financial health score for Palomino Labs Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Palomino Labs Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Palomino Labs Inc reported a net loss of $3.2M while operations used $1.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Palomino Labs Inc's EBITDA was -$1.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Palomino Labs Inc reported a net loss of $1.4M in Q2 2026. This represents a decrease of 450.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Palomino Labs Inc earned -$0.06 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Palomino Labs Inc recorded an outflow of $2.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Palomino Labs Inc held $19.4M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Palomino Labs Inc's quarterly ROE was -6.6% in Q2 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 11.1 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Palomino Labs Inc invested $669K in research and development in Q2 2026. Against the prior quarter it is up 52.6%.
Palomino Labs Inc invested $941K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is up 195.7%.
Not reported for Q2 2026.
PALX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $669K | $438K | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $697K+106.4% | $805K+4417.4% | N/A | $1.6M+129958.5% | $337K | $18K | N/A | $1K |
| Operating Income | -$1.4Mn/m | -$1.2Mn/m | N/A | -$1.6Mn/m | -$337K | -$18K | N/A | -$1K |
| EBITDA | -$1.4M | -$1.2M | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | $8K | $14K | N/A | N/A |
| Net Income | -$1.4M-450.5% | -$1.2M | N/A | -$1.8M | $389K+112448.3% | N/A | N/A | N/A |
| EPS (Basic) | -$0.06 | -$0.07 | N/A | -$0.54 | $0.15 | -$0.44 | -$0.01n/m | $0.00 |
| EPS (Diluted) | -$0.06 | -$0.07 | N/A | -$0.54 | $0.15 | -$0.44 | -$0.01n/m | $0.00 |
| Diluted Shares (Avg) | 22M | 19M | N/A | 3M | 3M | 2M | N/A | 2M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
PALX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.0M+1089.2% | $7.4M+40304.5% | $8.4M+6006.2% | $8.3M+2581502.8% | $1.8M+549417.4% | $18K+4694.7% | $138K-1.0% | $322-15.3% |
| Current Assets | $19.6M+1023.2% | $6.8M+37361.6% | $8.4M+6006.2% | N/A | $1.7M+541653.4% | $18K+4694.7% | $138K+36248.7% | $322-15.3% |
| Cash & Equivalents | $19.4M+1028.1% | $6.7M | $8.1M+5931.2% | $7.9M | $1.7M | N/A | $135K-3.5% | N/A |
| Short-Term Investments | $0n/m | $0 | $0n/m | $0 | $0 | N/A | $0n/m | N/A |
| Long-Term Investments | $0n/m | $0 | $0n/m | $0 | $0 | N/A | $0n/m | N/A |
| Total Liabilities | $476K-78.5% | $352K-65.1% | $336K+115.1% | $999K+11429.3% | $2.2M+95001.5% | $1.0M+5304.4% | $156K+10.4% | $9K-89.0% |
| Current Liabilities | $369K+182.6% | $229K-32.1% | $336K+5131.8% | $999K | $131K | $337K | $6K+24.0% | N/A |
| Non-Current Liabilities | $107K-94.9% | $123K-81.7% | $0-100.0% | $0 | $2.1M | $673K | $150K+9.9% | N/A |
| Total Equity | $20.6Mn/m | $7.0Mn/m | $8.1Mn/m | $7.3Mn/m | -$447Kn/m | -$992Kn/m | -$18Kn/m | -$8Kn/m |
| Retained Earnings | -$5.8Mn/m | -$4.4Mn/m | -$3.2Mn/m | -$2.4Mn/m | -$614Kn/m | -$319Kn/m | -$18Kn/m | -$222Kn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PALX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1Mn/m | -$1.1M-36681.5% | -$894Kn/m | -$310K-269458.3% | -$84K | $3K | -$6Kn/m | $115 |
| Depreciation & Amortization | $12K | $3K | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock-Based Compensation | $101K-35.1% | N/A | N/A | $1.3M | $155K | N/A | N/A | N/A |
| Capital Expenditures | $941K | $318K | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$2.1M | -$1.4M | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$941K | -$318K | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $14.9M+789.3% | -$30K-150100.0% | $1.1M+673.1% | $6.5M | $1.7M | $20 | $145K+155.0% | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PALX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'2510-Q | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -6.6% | -17.7% | N/A | -24.9% | N/A | N/A | N/A | N/A |
| Return on Assets | -6.5%-28.5pp | -16.9% | N/A | -21.9% | 22.0%-85.4pp | N/A | N/A | N/A |
| Current Ratio | 53.12+39.7x | 29.82+29.8x | 25.07+3.6x | N/A | 13.37 | 0.05 | 21.48+21.4x | N/A |
| Liabilities-to-Equity | 0.02 | 0.05 | 0.04 | 0.14 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Where Palomino Labs Inc Ranks
Frequently Asked Questions
No, Palomino Labs Inc (PALX) reported a net loss of $3.2M in fiscal year 2025.
Palomino Labs Inc (PALX) has a return on equity of -39.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Palomino Labs Inc (PALX) recorded an outflow of $1.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Palomino Labs Inc (PALX) had $8.4M in total assets as of fiscal year 2025, including both current and long-term assets.
Palomino Labs Inc (PALX) had a current ratio of 25.07 as of fiscal year 2025, which is generally considered healthy.
Palomino Labs Inc (PALX) had a liabilities-to-equity ratio of 0.04 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Palomino Labs Inc (PALX) had a return on assets of -37.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Palomino Labs Inc (PALX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Palomino Labs Inc (PALX) reported a net loss of $3.2M while operations used $1.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.